Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Multi-Center, Open-Label, Dose Finding Study of CC-122 in Combination With Sorafenib in Subjects With Unresectable Hepatocellular Carcinoma

NCT02323906 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02323906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02323906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Multi-Center, Open-Label, Dose Finding Study of CC-122 in Combination With Sorafenib in Subjects With Unresectable Hepatocellular Carcinoma
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Terminated
Start date
January 16, 2015
Completion date
December 21, 2016
Enrollment
12 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular